BR112023015461A2 - Métodos e biomarcadores para câncer - Google Patents

Métodos e biomarcadores para câncer

Info

Publication number
BR112023015461A2
BR112023015461A2 BR112023015461A BR112023015461A BR112023015461A2 BR 112023015461 A2 BR112023015461 A2 BR 112023015461A2 BR 112023015461 A BR112023015461 A BR 112023015461A BR 112023015461 A BR112023015461 A BR 112023015461A BR 112023015461 A2 BR112023015461 A2 BR 112023015461A2
Authority
BR
Brazil
Prior art keywords
methods
biomarkers
cancer
prognostic
genotype
Prior art date
Application number
BR112023015461A
Other languages
English (en)
Inventor
M Lippman Scott
Teresa Davoli
K Cavenee Webster
Original Assignee
Univ New York
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York, Univ California filed Critical Univ New York
Publication of BR112023015461A2 publication Critical patent/BR112023015461A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

métodos e biomarcadores para câncer. a divulgação proporciona adicionalmente métodos diagnósticos, prognósticos e terapêuticos, que são baseados, pelo menos em parte, na determinação da identidade de um genótipo de interesse identificado no presente documento.
BR112023015461A 2021-02-05 2022-02-04 Métodos e biomarcadores para câncer BR112023015461A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163146191P 2021-02-05 2021-02-05
US202163179215P 2021-04-24 2021-04-24
PCT/US2022/015363 WO2022170131A1 (en) 2021-02-05 2022-02-04 Methods and biomarkers in cancer

Publications (1)

Publication Number Publication Date
BR112023015461A2 true BR112023015461A2 (pt) 2023-10-10

Family

ID=82741831

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023015461A BR112023015461A2 (pt) 2021-02-05 2022-02-04 Métodos e biomarcadores para câncer

Country Status (5)

Country Link
US (1) US20240093303A1 (pt)
EP (1) EP4288090A1 (pt)
JP (1) JP2024509360A (pt)
BR (1) BR112023015461A2 (pt)
WO (1) WO2022170131A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024039692A1 (en) * 2022-08-16 2024-02-22 The Regents Of The University Of California Chromosome 9p24 loss and gain predicts resistance and benefit of immune checkpoint inhibitors
WO2024076925A1 (en) * 2022-10-03 2024-04-11 The Regents Of The University Of California Genetically defined immune-checkpoint inhibitor resistance in aggressive precursors of hpv--head and neck squamous cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067092A1 (en) * 2017-08-07 2019-04-04 The Johns Hopkins University METHODS AND SUBSTANCES FOR THE EVALUATION AND TREATMENT OF CANCER

Also Published As

Publication number Publication date
JP2024509360A (ja) 2024-03-01
WO2022170131A1 (en) 2022-08-11
EP4288090A1 (en) 2023-12-13
US20240093303A1 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
BR112023015461A2 (pt) Métodos e biomarcadores para câncer
MX2022006589A (es) Predictor de respuesta de platino pan-cancer.
BR112018015698A2 (pt) ?métodos diagnósticos e prognósticos para doenças cardiovasculares e eventos?
BR112021022879A2 (pt) Sistemas e métodos para avaliação de fração tumoral
ZA202000935B (en) Methods and materials for assessing and treating cancer
WO2018187496A8 (en) PLASMA PROTEIN PROFILING FOR THE EARLY PROGNOSIS OF LUNG CANCER
BR112017014134A2 (pt) método de verificação de uma linha flexível e instalação para verificar uma linha flexível
BR112016014387A2 (pt) Sistemas, métodos e aparelho para composição e/ou recuperação digital
BR112018004593A2 (pt) sistemas e métodos para atualizar dados de contas de proprietários de cartões
BR112017004773A2 (pt) biomarcadores para avaliar câncer de mama
BR112015018463A2 (pt) Biomarcadores de diabetes tipo 2 e usos dos mesmos
CO2019002608A2 (es) Biomarcadores de arn para angioedema hereditario
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
BR112015022556A2 (pt) estruturas de sola e artigos de calçado tendo palmilhas leves com elementos de proteção
BR112013011590A2 (pt) método de tratamento de câncer
BR112017016752A2 (pt) métodos para determinar o risco de recidiva de câncer de endométrio em um indivíduo, para predizer a recidiva em um indivíduo com câncer de endométrio, para orientar o tratamento em um indivíduo com câncer de endométrio, para detectar a instabilidade de microssatélites, e, para determinar subtipos de câncer
BR112017025681A2 (pt) sistema e método para um servidor do sistema de criação de website
BR112018008799A2 (pt) método de prognóstico
BR112017019841A2 (pt) técnica de análise de amostra de tecido
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
BR112019009565A2 (pt) método de avaliação da cinética molecular e método de rastreamento
BR112022006013A2 (pt) Dispositivo e método para a determinação não inva-siva de analito
BR112016028505A2 (pt) método para produzir um item de informação de autenticidade de um elemento de segurança e elemento de segurança
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto
BR112018009879A2 (pt) biomarcador da doença renal policística e seus usos